Skip to content
OpenCapital
Get started

Aclaris Therapeutics ACRS Single Reportable — Research And Development Expense Other

Similar metrics at other companies

Alumis Inc. logo
ALMSSingle Reportable — Other Research And Development Expense
$2.37M+3.2%
Celldex Therapeutics logo
CLDXSingle Reportable — Other Research And Development Expense
$4.88M+48.9%
Lantheus Holdings logo
LNTHReportable — Other Research And Development Expense
$27.59M-1.1%
Inhibrx Biosciences, Inc. logo
INBXReportable Segment — Other Research and Development Expense
$2.91M-7.8%
Crinetics Pharmaceuticals logo
CRNXReportable Segment — Other Research and Development Expense
$8.3M+23.2%
Travere Therapeutics, Inc. logo
TVTXReportable Segment — Other research and development
$4.84M+9.2%

Other financials

Income statement

See full
Revenue$2.0M+37.2%
Gross profit$1.6M+68.7%
Operating income-$22.2M-22.7%
Net income-$19.8M-31.4%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$28.7M-5.6%
Total debt$2.0M-20.1%
Total equity$143.6M-0.3%
Total assets$198.7M+0.3%

Cash flow

See full
Operating cash flow-$18.1M-39.0%
CapEx$13.0K-69.8%
Free cash flow-$18.2M-38.6%

Valuation

See full
Market cap$685.75M+337%
Enterprise value$659.07M+410%
P/S82×+73.1×

Profitability

See full
Gross margin76.3%-9.7pp
Operating margin-961.9%+259pp
Net margin-832.6%+132pp
FCF margin-624.9%—

Returns & leverage

See full
Return on equity-48.4%-15.4pp
Debt / equity0×0.0×
Current ratio4×-1.0×

Where this comes from

Reported directly by Aclaris Therapeutics in its filing.

Tagged under the XBRL concept acrs:ResearchAndDevelopmentExpenseOther.

The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aclaris Therapeutics's single reportable — research and development expense other.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aclaris Therapeutics's single reportable — research and development expense other?
Aclaris Therapeutics (ACRS) reported single reportable — research and development expense other of $1.9M in Q1 2026.
How has Aclaris Therapeutics's single reportable — research and development expense other changed year-over-year?
Aclaris Therapeutics's single reportable — research and development expense other increased by 26.6% year-over-year, from $1.5M to $1.9M.
What does single reportable — research and development expense other mean?
Encompasses miscellaneous research and development costs not categorized as personnel charges, such as laboratory supplies, equipment maintenance, or third-party research services. This metric provides insight into the non-labor operational intensity of the segment's innovation efforts. It helps investors understand the overhead required to support scientific discovery.